All In Biotech

Drug Trial Radar · NCT00599196

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Oct 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

381

Actual

Start

Aug 2002

Primary completion

Dec 2008

Study completion Dec 2008

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Jan 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease

Conditions

  • Early Stage Parkinson's Disease

Interventions

  • RotigotineDrug

    Rotigotine trans-dermal patches, once daily: 10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours); Optimal dosing: During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours. After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With at Least One Adverse Event During This Open-label Extension StudyTime frame: six years

Locations

63 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    Concord, Australia

  • Site not named

    Darlinghurst, Australia

  • Site not named

    East Gosford, Australia

  • Site not named

    Westmead, Australia

  • Site not named

    Innsbruck, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Brussels, Belgium

  • Site not named

    Hoboken, Belgium

  • Site not named

    Zagreb, Croatia

  • Site not named

    Brno, Czechia

  • Site not named

    Ostrava, Czechia

  • Site not named

    Pilsen, Czechia

  • Site not named

    Espoo, Finland

  • Site not named

    Kuopio, Finland

  • Site not named

    Lappeenranta, Finland

  • Site not named

    Oulu, Finland

  • Site not named

    Pori, Finland

  • Site not named

    Aix-en-Provence, France

  • Site not named

    Caen, France

  • Site not named

    Toulouse, France

  • Site not named

    Aachen, Germany

  • Site not named

    Dresden, Germany

  • Site not named

    Kiel, Germany

  • Site not named

    Marburg, Germany

  • Site not named

    Budapest, Hungary

  • Site not named

    Miskolc, Hungary

  • Site not named

    Pécs, Hungary

  • Site not named

    Hadera, Israel

  • Site not named

    Petah Tikva, Israel

  • Site not named

    Tel Aviv, Israel

  • Site not named

    Milan, Italy

  • Site not named

    Padova, Italy

  • Site not named

    Pozzilli, Italy

  • Site not named

    Breda, Netherlands

  • Site not named

    Geldrop, Netherlands

  • Site not named

    Auckland, New Zealand

  • Site not named

    Christchurch, New Zealand

  • Site not named

    North Shore, New Zealand

  • Site not named

    Wellington, New Zealand

  • Site not named

    Stavanger, Norway

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.